Persistent Systems has partnered with Nvidia to develop AI-driven software for healthcare and life sciences, focusing on computational drug discovery with the launch of their new product, Generative Molecules and Virtual Screening (GenMolVS). This collaboration utilizes Nvidia’s AI software stack and accelerated computing systems to enhance research and development within the biopharma sector. As healthcare firms face increasing pressures for productivity under strict regulations, computational methods, including molecular simulation and virtual screening, are becoming vital in early-stage discovery. GenMolVS leverages Nvidia BioNeMo and NeMo Agent Toolkit to streamline workflows, linking simulation outcomes with laboratory experiments for real-time decision-making. Furthermore, Persistent plans to create production-grade agentic AI applications, facilitating improved drug discovery processes. This initiative aligns with the industry’s shift towards AI, enabling biopharma companies to accelerate the discovery of new therapies efficiently. Overall, the collaboration represents a significant step in operationalizing AI in mission-critical healthcare applications.
Source link
